Hepatitis C virus (HCV) infection has a high prevalence in people who inject drugs in Europe, although HCV infection is both preventable and curable. Effective interventions that target the prevention of HCV transmission and the treatment of hepatitis C are needed, particularly for so-called ‘hard to reach’ and vulnerable populations.
Increasing access to hepatitis C care through drugs services
People who inject drugs are a key population for the elimination of hepatitis C in Europe; increasing access to HCV testing and care for this group is a goal in European and national hepatitis C policies. This EMCDDA Harm Reduction initiative provides a set of new materials and tools to help countries to analyse barriers to testing at drug services, to identify solutions in collaboration with all stakeholders involved and to implement new models of care in this field.Learn more
Activities and tools
EMCDDA activities, services and tools on this topic